Zacks Research Has Strong Estimate for BDX FY2025 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Investment analysts at Zacks Research boosted their FY2025 earnings estimates for shares of Becton, Dickinson and Company in a report issued on Wednesday, February 26th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will earn $14.43 per share for the year, up from their prior estimate of $14.36. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q4 2026 earnings at $4.54 EPS, FY2026 earnings at $15.60 EPS and FY2027 earnings at $16.84 EPS.

Other analysts have also recently issued reports about the company. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday. Piper Sandler increased their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Finally, Barclays increased their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $278.29.

Becton, Dickinson and Company Price Performance

NYSE BDX opened at $224.46 on Monday. The business has a 50 day simple moving average of $233.07 and a 200 day simple moving average of $232.89. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The stock has a market cap of $64.45 billion, a price-to-earnings ratio of 37.29, a PEG ratio of 1.63 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%.

Hedge Funds Weigh In On Becton, Dickinson and Company

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of Jackson Hole Trust bought a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at $25,000. Sierra Ocean LLC bought a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at $29,000. REAP Financial Group LLC grew its stake in shares of Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 55 shares in the last quarter. Picton Mahoney Asset Management grew its stake in shares of Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 54 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in shares of Becton, Dickinson and Company in the third quarter valued at $33,000. 86.97% of the stock is owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP David Shan sold 500 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the transaction, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the transaction, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. This represents a 15.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,544 shares of company stock valued at $2,370,309 in the last ninety days. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.85%. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.